ERBB2 and breast cancer: The above clinical analyses demonstrated a pleiotropic effect of PIK3CA mutations which were stage dependent, PIK3CA mutations were associated with improved DFS in all HER2+ breast cancer patients, but served as an indicator of poor response to continuous trastuzumab‐based treatments in locally advanced or advanced HER2+ cohorts.